Research Updates on Hydrogen Therapy: From Jan 2020 to Aug 2020
Are there things about hydrogen therapy that we know now that we didn't know in 2019? We have compiled major scientific publications related to "hydrogen therapy" and "molecular hydrogen" that are published this year in 2020 and summarised essential information below in layman's terms so that you can understand and make a better informed decision.
If you are new to hydrogen therapy, check out Hydrogen Water As An Antioxidant: A Research Update.
Due to the fast-changing pace of research and technology, new evidence accumulates rapidly and clinical guidelines need to be periodically updated.
1. Molecular hydrogen: A potential radioprotective agent
Published in August 2020 (Biomed Pharmacother. 2020), this review aims to provide an overview of recent findings in this field that studied the radioprotective effect of hydrogen treatment.
Presently ionizing radiation (IR) has extensive applications in medical diagnostics (e.g. CT scan) and tumor therapy (e.g.Radiotherapy).
There has always been a strong demand for safe and potent radioprotectants. The only U.S. FDA approved radioprotectant available today is the synthetic thiol amifostine. However, it has many shortcomings such as short protection time, unfavorable routes of administration, and comparatively high toxicity. Natural antioxidants such as melatonin, vitamin E, and others, while having fewer adverse effects, they also offer much weaker protection compared against thiol agents. H2 can be easily applied with little adverse effects and great efficacy as a potential radioprotective agent. This article reviewed up to date medical progress related to H2 as a radioprotectant, covering its unique properties, potential mechanisms of action, delivery techniques, findings in vitro/vivo studies even clinical practice.
Published in June 2020 (Reactive Oxygen Species), the aim is to review the current research into COVID-19 and to better understand how treatment with molecular hydrogen is likely to affect cellular responses during COVID-19 infection.
3. Hydrogen therapy can be used to control tumor progression and alleviate the adverse events of medications in patients with advanced non-small cell lung cancer (NSCLC)
Published in June 2020 (Journal of Thoracic Disease. 2020), this China study is the first multicenter randomized clinical trial that verifies the efficacy and safety of H2-O2 (mixed hydrogen gas and oxygen gas) inhalation in patients (n=90) with COVID-19.
Patients with COVID-19 frequently presented with dyspnea, coughing, chest pain and distress, and oxygen desaturation which cannot be rapidly relieved with other existing therapies (including oxygen therapy). The therapeutic effects of H2-O2 became significant as early as days 2 and 3 and the reduction of most respiratory symptoms persisted till the end-of-treatment.
The authors also concluded that the safety profiles of H2-O2 have rendered H2-O2 inhalation particularly suitable for relieving difficulty in breathing and other breathing symptoms in patients with COVID-19, regardless of the disease severity.
5. Hydrogen and therapeutic gases for neonatal hypoxic-ischemic encephalopathy: potential neuroprotective adjuncts in translational research
Published in June 2020 (Pediatric Research 2020), researchers review therapeutic gases, particularly hydrogen, and their potentials and limitations in the treatment of HIE (Hypoxic Ischemic Encephalopathy) in newborns.
In translational research into adult diseases, hydrogen has been shown to be neuroprotective in disorders such as cerebral ischemia and traumatic brain injury, and in neurodegenerative diseases such as Alzheimer's disease.
However, despite extensive research on its effectiveness in adults, only a few studies have investigated its application in pediatric and neonatal medicine. Neonatal hypoxic–ischemic encephalopathy (HIE) is characterized by damage to neurons and other cells of the nervous system. One of the major contributing factors is excessive exposure to oxidative stress. Current research interest in HIE is shifting toward new neuroprotective agents, as single agents or as adjuncts to therapeutic hypothermia.
Hydrogen ventilation as a single agent or in combination with therapeutic hypothermia shows short- and long-term neuroprotection in neonatal translational HIE models.
Hydrogen Water Safety, Dosage, Side effects
Molecular hydrogen (H2) has no known side effects. It’s not toxic even at high concentrations. However, the long-term risks remain unknown until additional studies are carried out [R].
In most clinical studies, people drank 0.5 – 2 L of hydrogen water daily.
After drinking hydrogen water, about 40% of the H2 is absorbed by the body [R].
Where to Buy Hydrogen Water in Malaysia?
You can purchase Izumio hydrogen water from an authorised distributor in Malaysia. For more information, please feel free to WhatsApp: +60 12-749 2112.
Related:
If you are new to hydrogen therapy, check out Hydrogen Water As An Antioxidant: A Research Update.
Due to the fast-changing pace of research and technology, new evidence accumulates rapidly and clinical guidelines need to be periodically updated.
Here, we have listed and compiled all significant scientific publications related to hydrogen therapy for the year 2020. The list was complied by running various searches on PubMed. Each study is hyperlinked to the abstract in the U.S. National Library of Medicine or the full text article to make it easier for healthcare providers or scientists to access more details. The list was complied by running various searches on PubMed.
This article contains information and links to a list of major hydrogen therapy resources and research published in the year 2020. This list is a work-in-progress list as new evidence might be added from time to time.
In order to make it consumer friendly, we have tried to summarise the studies and minimise the technical jargons.
Here is the list.
This article contains information and links to a list of major hydrogen therapy resources and research published in the year 2020. This list is a work-in-progress list as new evidence might be added from time to time.
Here is the list.
1. Molecular hydrogen: A potential radioprotective agent
Published in August 2020 (Biomed Pharmacother. 2020), this review aims to provide an overview of recent findings in this field that studied the radioprotective effect of hydrogen treatment.
Presently ionizing radiation (IR) has extensive applications in medical diagnostics (e.g. CT scan) and tumor therapy (e.g.Radiotherapy).
There has always been a strong demand for safe and potent radioprotectants. The only U.S. FDA approved radioprotectant available today is the synthetic thiol amifostine. However, it has many shortcomings such as short protection time, unfavorable routes of administration, and comparatively high toxicity. Natural antioxidants such as melatonin, vitamin E, and others, while having fewer adverse effects, they also offer much weaker protection compared against thiol agents. H2 can be easily applied with little adverse effects and great efficacy as a potential radioprotective agent. This article reviewed up to date medical progress related to H2 as a radioprotectant, covering its unique properties, potential mechanisms of action, delivery techniques, findings in vitro/vivo studies even clinical practice.
2. An Overview of SARS-CoV-2 (COVID-19) Infection and the Importance of Molecular Hydrogen as an Adjunctive Therapy
Application of H2, may provide an effective adjunctive medicament to O2 inhalation in the treatment of COVID-19 for the critically ill. Although this method is recommended and practiced in the People’s Republic of China with oxygen/hydrogen mixed gas noted to significantly reduce dyspnea, it is not widely used elsewhere. To date, only one clinical trial using oxyhydrogen for the treatment of COVID-19 infection has been registered with the US National Library of Medicine, with a further four clinical trials registered with The Centre for Evidence-Based Medicine (CEBM).
It is the authors’ opinion that inhalation of H2 would be a more effective delivery mechanism for patients with moderate/severe symptoms of COVID19. Also worthy of notation is that currently, most, but not all clinical trials have been based on inhalation of H2, with this also being the preferred delivery method as recommended by The National Health Commission of the People's Republic of China.
Published in Apr - June 2020 issue of Med Gas Res, 58 patients with advanced non-small lung cancer were enrolled into 5 groups:
After 16 months of follow-up, progression-free survival of the control group was lower than that of the H2-only group, and significantly lower than that of H2 + chemotherapy, H2 + targeted therapy, and H2 + immunotherapy groups.
This study was associated with the clinical trial NCT03818347.
4. Hydrogen/oxygen mixed gas inhalation improves disease severity and dyspnea in patients with Coronavirus disease 2019 in a recent multicenter, open-label clinical trial
1) refused drug treatment (control group)
2) refused drug treatment (hydrogen therapy only)
3) H2 + chemotherapy,
4) H2 + targeted therapy, and
5) H2 + immunotherapy group.
After 16 months of follow-up, progression-free survival of the control group was lower than that of the H2-only group, and significantly lower than that of H2 + chemotherapy, H2 + targeted therapy, and H2 + immunotherapy groups.
This study was associated with the clinical trial NCT03818347.
4. Hydrogen/oxygen mixed gas inhalation improves disease severity and dyspnea in patients with Coronavirus disease 2019 in a recent multicenter, open-label clinical trial
Published in June 2020 (Journal of Thoracic Disease. 2020), this China study is the first multicenter randomized clinical trial that verifies the efficacy and safety of H2-O2 (mixed hydrogen gas and oxygen gas) inhalation in patients (n=90) with COVID-19.
Patients with COVID-19 frequently presented with dyspnea, coughing, chest pain and distress, and oxygen desaturation which cannot be rapidly relieved with other existing therapies (including oxygen therapy). The therapeutic effects of H2-O2 became significant as early as days 2 and 3 and the reduction of most respiratory symptoms persisted till the end-of-treatment.
The authors also concluded that the safety profiles of H2-O2 have rendered H2-O2 inhalation particularly suitable for relieving difficulty in breathing and other breathing symptoms in patients with COVID-19, regardless of the disease severity.
5. Hydrogen and therapeutic gases for neonatal hypoxic-ischemic encephalopathy: potential neuroprotective adjuncts in translational research
Published in June 2020 (Pediatric Research 2020), researchers review therapeutic gases, particularly hydrogen, and their potentials and limitations in the treatment of HIE (Hypoxic Ischemic Encephalopathy) in newborns.
However, despite extensive research on its effectiveness in adults, only a few studies have investigated its application in pediatric and neonatal medicine. Neonatal hypoxic–ischemic encephalopathy (HIE) is characterized by damage to neurons and other cells of the nervous system. One of the major contributing factors is excessive exposure to oxidative stress. Current research interest in HIE is shifting toward new neuroprotective agents, as single agents or as adjuncts to therapeutic hypothermia.
Hydrogen ventilation as a single agent or in combination with therapeutic hypothermia shows short- and long-term neuroprotection in neonatal translational HIE models.
6. A "philosophical molecule," hydrogen may overcome senescence and intractable diseases
Published in the Jan-Mar 2020 issue (Med Gas Res. Jan-Mar 2020), this review of molecular hydrogen (H2) aims to propose a safe H2 medical use with no adverse effects. H2 may be able to solve various medical problems by combining with modern treatment or as a stand-alone. According to the authors:
From the viewpoint of the longevity of the youth, oxidation means “senescence” while reduction means “rejuvenation.” In this paper, we propose the possibility that H2 will overcome the senescence and intractable diseases from the viewpoint of mitochondrial oxidation and reduction.
In conclusion, only H2 can penetrate into the mitochondria and can also scavenge reactive oxygen species (ROS). Thereby, the H2 in the body can contribute towards disease prevention and recovery.
Up to now there are more than 600 papers regarding the use of H2 , including about 50 clinical trials papers. The use of H2 is indispensable in the future, and we would like to advocate the promotion of hydrogen medicine.
Conclusion
As of August 2020, there are 125 on-going clinical studies related to "molecular hydrogen" on clinicaltrials.gov. Hydrogen medicine is a new and dynamic field with many on-going research. This list is a work-in-progress list as new evidence might be added from time to time.In most clinical studies, people drank 0.5 – 2 L of hydrogen water daily.
After drinking hydrogen water, about 40% of the H2 is absorbed by the body [R].
Where to Buy Hydrogen Water in Malaysia?
Related:
Comments
Post a Comment